Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc in Post-stroke Cognitive Impairment
NCT04966429Phase 2Unknown
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- May 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of maraviroc in post-stroke cognitive impairment (PSCI), sponsored by Tel Aviv Sourasky Medical Center. Status: unknown.
02
Drugs
maraviroc
03
Conditions
post-stroke cognitive impairment (PSCI)
Beyond the preview
Go deeper on NCT04966429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04966429.